B-Myb is a highly conserved member of the Myb transcription factor family. The primary transcript of the B-myb gene is spliced alternatively in two mRNAs which either contain or lack a sequence corresponding to the so-called exon 9A of c-myb. Recent studies showed that full-length B-Myb containing the exon 9A encoded amino acids is a cell cycle regulated transcription factor whose activity is stimulated by cyclin A/Cdk 2-dependent phosphorylation at the carboxyl-terminus of B-Myb. We have now investigated in more detail the transactivation potential of the shorter isoform of B-Myb lacking exon 9A. Here, we show that B-Myb lacking exon 9A has no transactivation activity even in the presence of cyclin A. This inactivity of the shorter isoform of B-Myb is not due an improper subcelluar localization. Our work suggests that B-Myb lacking exon 9A may act as an inhibitor for full-length B-Myb mediated transactivation. Furthermore, by analysing the transactivation potential of Gal4/B-Myb fusion proteins we have identi®ed the amino-terminal part of the exon 9A as the principal transactivation domain of full-length B-Myb. The results presented here demonstrate that B-myb encodes both an activator and an inhibitor of transcription and, thus, reveal an additional level of regulation of B-Myb activity beside the known cyclin dependent mechanisms.
Introduction
The myb gene family consists of three members, Amyb, B-myb and c-myb (Nomura et al., 1988) . The distinctive feature of the Myb proteins is a highly conserved N-terminal domain which consist of three imperfect repeats, each 50 ± 52 amino acids in length, and constitute a DNA binding domain (Klempnauer and Sippel, 1987; Biedenkapp et al., 1988) . C-myb, the cellular homolog of the v-myb oncogene of the avian myeloblastosis virus, is the best studied member of this family and encodes the transcription factor c-Myb which is essential for the proliferation and dierentiation of hematopoietic precursor cells (for review see: Graf, 1992; Ness, 1996; Oh and Reddy, 1999) . In addition to the amino terminal DNA binding domain, c-Myb contains a transactivation domain located in the middle of the protein and a negative regulatory domain at the C-terminus (Sakura et al., 1989; Weston and Bishop, 1989) . C-terminal truncation of c-Myb leads to an increase in the transactivational activity of the protein and activates its oncogenic potential (Grasser et al., 1991; Gonda et al., 1989; Hu et al., 1991) . The proteins encoded by the A-myb and B-myb genes, referred to as A-Myb and B-Myb, share limited homology with the transactivation and negative regulatory domains in addition to the DNA-binding domain, and also act as transcription factors. While the functions of c-myb and A-myb appear to be restricted to speci®c cell types (Graf, 1992; Trauth et al., 1994; Toscani et al., 1997) , B-myb is expressed in a wide variety of dividing cells and seems to play a general role during cell proliferation (Sitzmann et al., 1996; Saville and Watson, 1998a) . Growth arrest of serumstarved ®broblasts leads to a down-regulation of B-myb expression; subsequent stimulation of these cells by serum induces E2F-dependent expression of B-myb in the late G1/early S phase of the cell cycle (Lam et al., 1992; Lam and Watson, 1993; Zwicker et al., 1996) . Antisense-inhibition of B-myb mRNA leads to growth arrest (Arsura et al., 1992; Sala and Calabretta, 1992) while overexpression of B-myb leads to an increase in the number of cells in S phase (Sala et al., 1996; Lane et al., 1997) . In addition, constitutive expression of Bmyb can bypass the Cip/WAF-1 mediated growth arrest in G1 (Lin et al., 1994) . These ®ndings suggest an important role for B-myb in the transition of cells from G1 into S-phase.
Previous studies have shown that c-myb mRNA is spliced dierentially. An additional exon (referred to as exon 9A) is present in a minor fraction of c-myb mRNA but is missing from the major c-myb mRNA species (Rosson and Reddy, 1987; Shen-Ong, 1987; Dasgupta and Reddy, 1989; Shen-Ong et al., 1989; Schuur et al., 1993) . The major translation product of c-myb is a 75 kD protein, while exon 9A containing c-myb mRNA encodes a 89 kD protein with an additional amino acid sequence located in the carboxy terminal half of the protein. Interestingly, sequences related to the exon 9A of c-myb are also found in A-myb and B-myb (Foos et al., 1992 (Foos et al., , 1994 Trauth et al., 1994) . Recent studies demonstrate that dierential splicing is not restricted to c-myb, but also occurs in the B-myb gene (Kamano et al., 1995) . However, there is a major dierence in the relative abundance of the two mRNA species between c-myb and B-myb. In contrast to c-myb, the B-myb RNA species containing the exon 9A is the predominant form. Both splicing variants of B-myb mRNA are expressed in a large number of dierent cell types at similar levels (Kamano et al., 1995) . In A-myb, an alternatively spliced product lacking the exon 9A region has not been found so far. Instead, dierentially spliced products with truncations in the C-terminal region have been identi®ed (Mettus et al., 1994) .
Earlier studies had shown that the proteins encoded by the two isoforms of B-Myb are unable to activate promoters to which they bind (Kamano et al., 1995) . Recently, however, we and others have found that BMyb containing exon 9A is a cell cycle regulated transactivator whose activity is dependent on cyclin A/ Cdk2-mediated phosphorylation (Robinson et al., 1996; Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997; Saville and Watson, 1998b; Bartsch et al., 1999) .
The observation that the activity of full-length BMyb is regulated by cyclin A-dependent phosphorylation raised the question whether the isoform of B-Myb lacking exon 9A is also regulated by the same mechanism, or whether it remains inactive even in the presence of cyclin A and acts as an inhibitor of transcription. Here, we have investigated in more detail the transactivation potential of the shorter isoform of B-Myb. We show that B-Myb lacking exon 9A inhibits transcription even in the presence of cyclin A/Cdk2. We have also mapped the transactivation domain of B-Myb and show that an essential part of it is encoded by the exon 9A, thus explaining the lack of activity of the shorter isoform of B-Myb.
Results and discussion
B-Myb lacking exon 9A is unable to stimulate transcription of a Myb-dependent reporter gene Previous studies have shown that the proteins encoded by the alternatively spliced B-myb mRNAs are both unable to stimulate the expression of Mybdependent reporter genes (Kamano et al., 1995) . Subsequently, we and others have shown that the transactivation potential of full-length B-Myb (i.e. BMyb containing exon 9A) is repressed by the Cterminus of the protein and can be activated by cyclin A/Cdk2-dependent phosphorylation (Robinson et al., 1996; Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997; Saville and Watson, 1998b; Bartsch et al., 1999) . However, these studies focused exclusively on the regulation of full-length B-Myb and did not address the possibility that the activity of the shorter form of B-Myb (i.e. B-Myb lacking the exon 9A encoded sequences) is also regulated by the same mechanism. Thus, the question whether or not the shorter form of B-Myb acts as a cell-cycle regulated transcriptional activator, like the full-length protein, or acts as a repressor remained open. To address this issue, we compared the ability of full-length B-Myb and B-Myb lacking the exon 9A to activate the Mybdependent reporter gene pGl3-3xATk in the presence of cyclin A. As expected, full-length B-Myb strongly stimulated the reporter gene while the shorter form of B-Myb had no eect (Figure 1a) , although the protein levels of B-Myb lacking exon 9A were higher than protein levels of full-length B-Myb (Figure 1b) . Thus, the failure of the shorter form of B-Myb to transactivate the reporter gene was not due to insucient amounts of the protein. This lack of transactivation potential was also not due to using a particular cell line for transfection experiments. We also performed similar transactivation experiments using Cos7 instead of QT6 cells (as in Figure 1 ), however, all observed eects were similar in both cell lines (data not shown).
Both isoforms of B-Myb are located in the nucleus
The failure of the shorter form of B-Myb to activate the Myb-dependent reporter gene could be explained rather simply if the protein was not localized to the cell nucleus. In order to address this possibility, we compared the subcellular locations of full-length BMyb and the shorter isoform. Expression vectors for both variants of B-Myb were cotransfected with an expression vector for cyclin A (pRc/CycA) and cells were fractionated in nuclear and cytoplasmic probes. Figure 2 shows that both proteins were located predominantly in the cell nucleus, whereas only small amounts of both proteins were present in the cytoplasmic fractions. This result is in accordance with the observation that the subcellular location of c-Myb is not in¯uenced by the exon 9A (Dudek and Reddy, 1989a,b) . Thus, we concluded that both proteins occupy similar locations in the cell, suggesting that 
B-Myb lacking exon 9A inhibits transactivation mediated by full-length B-Myb
If B-Myb lacking exon 9A is unable to activate a Mybdependent reporter gene although it resides in the same cell compartment as full-length B-Myb it might act as an inhibitor of B-Myb mediated transactivation by competing with full-length B-Myb for the same binding sites. To address this idea, we studied the transactivation mediated by full-length B-Myb in the presence of increasing amounts of the shorter isoform of B-Myb. Figure 3a depicts the result of this experiment. We found that increasing amounts of B-Myb lacking the exon 9A indeed diminish transactivation mediated by full-length B-Myb. Figure 3b shows the protein levels of the two forms of B-Myb. It is apparent that the inhibition is not caused by a decrease of the protein level of full-length B-Myb. In the presence of the shorter form of B-Myb there is even slightly more of the full-length B-Myb, suggesting that the extent of inhibition caused by B-Myb lacking exon 9A is even higher than is apparent from Figure 3a .
The inhibitory eect illustrated in Figure 3a could be explained either by a competition of both B-Myb proteins for the same binding sites or by a competition for other components of the transcriptional machinery (e.g. coactivators). In order to discern between these possibilities, we asked whether the shorter form of BMyb also inhibits transactivation of a Gal4-dependent reporter gene by a Gal4/B-Myb fusion protein. If the shorter isoform of B-Myb inhibits transactivation by full-length B-Myb due to competing for the same binding sites, then the Gal4/B-Myb fusion protein should escape this inhibitory mechanism. If, on the other hand, both proteins compete for limiting components of the transcriptional machinery, then the shorter isoform of B-Myb should also inhibit transactivation mediated by the Gal4/B-Myb fusion protein. The result of this experiment is illustrated in Figure 3c . It is obvious that the activity of the Gal4/BMyb fusion protein was not repressed by the shorter splice variant of B-Myb, instead there was an increase in reporter gene activity. This increase presumably was due to a somewhat higher protein level of the Gal4/BMyb fusion protein in lane 3 compared to lane 2 of Figure 3d . In summary, the experiments shown in Figure 3 therefore suggest that the shorter form of BMyb acts as an inhibitor of full-length B-Myb by competing with it for the same binding sites.
Mapping of the transactivation domain of B-Myb
The results shown before suggest that the shorter form of B-Myb lacks transactivation potential and, presumably, functions as an inhibitory protein that counteracts the transactivation mediated by full-length B-Myb. In an attempt to further understand the reason for the dierent behavior of the two B-Myb proteins we set out to map the transactivation domain within BMyb. Comparison of the B-Myb aminoacid sequences from dierent vertebrates, such as chicken, mouse and human allowed us to identify several conserved regions in the center of B-Myb which are separated by less well conserved sequences. We reasoned that these conserved regions might represent functional domains of the protein. Interestingly, as illustrated in Figure 4a , the boundaries of the exon 9A did not coincide with the boundaries of these putative domains. To determine whether the B-Myb transactivation domain maps to one of the highly conserved regions, we expressed several of these regions as Gal4 fusion proteins and determined their ability to transactivate a Gal4-dependent reporter gene. Figure 5a illustrates schematically the dierent Gal4 fusion constructs generated. As illustrated in Figure 5b , the protein encoded by Gal4 B-Myb D2 was very active as a transactivator, while Gal4 B-Myb D1 and Gal4 B-Myb D3 were not active at all or very weakly active. The combination of domains 2 and 3 (Gal4 B-Myb D5) was also very active while the construct corresponding to domains 2 and 3 but lacking the sequences encoded by exon 9A (Gal4 B-Myb D4) was completely inactive. Figure 5c shows that all of the Gal4 fusion proteins were expressed in similar amounts. Taken together, the simplest explanation of these results is that domain 2, which is encoded in part by exon 9A, is the principal transactivation domain of B-Myb. Our results are consistent with previous mapping studies of the B-Myb transactivation domain performed in yeast (Ansieau et al., 1997) . The observation that the construct Gal4 BMyb D4 is inactive although it contains a part of domain 2 suggests that the C-terminal sequences of domain 2 which are encoded by exon 9A are essential for the activity of the transactivation domain. Thus, it appears that the shorter isoform of B-Myb fails to QT6 cells were transfected with 1 mg of expression vector for cyclin A (pRc/Cyc A) and 6 mg of expression vector for fulllength mouse B-Myb including exon 9A (pMuBMEx9A+) or 4 mg of expression vector for B-Myb lacking exon 9A (pMuBMEx9A7), as indicated. The amounts of B-Myb expression vectors transfected were adjusted such that both proteins were expressed at similar levels in the transfected cells. After 24 h transfected cells were fractionated into nuclear (N) and cytoplasmic (C) fractions. Equivalent amounts of both fractions were analysed by 10% SDS ± PAGE and Western blotting using antiserum against B-Myb. The bands corresponding to BMyb(Ex9A+) and B-Myb(Ex9A7) are marked with black and white arrowheads, respectively transactivate Myb-dependent reporter genes because it lacks an essential part of the transactivation domain. We cannot exclude that other regions in exon 9A contribute to the transactivation activity, however, the ®ndings that the Gal4 B-Myb fusion protein containing the conserved C-terminal region of exon 9A (Gal4 BMyb D3) is only a weak activator of transcription in comparison to Gal4 B-Myb D2 provides a strong argument for the importance of the N-terminal domain of exon 9A. Comparison of the exon 9A encoded aminoacid between A-Myb, B-Myb and c-Myb shows that the sequences which are located at the N-terminus are conserved (Figure 4b ). This suggests an important role for this region in A-Myb and c-Myb as well. In fact, the exon 9A including splicing variant of c-Myb is a stronger transactivator than c-Myb lacking exon 9A (Woo et al., 1998) . To analyse the role of the Nterminal region of exon 9A independently we have generated a Gal4 fusion protein containing only the sequences of domain 2 which are encoded by exon 9A. The resulting protein is a weak transactivator (data not shown). This suggests that these sequences by themselves are not sucient for ecient transactivation. Thus, most likely they act as an essential accessory element in conjunction with the N-terminal part of domain 2. Finally, it is worth pointing out that the protein encoded by Gal4 B-Myb D4 is able to repress transactivation in comparison to the Gal4 DNA-binding domain alone. This result raises the interesting possibility, that domains 2 and 3 act as a transcription repressing domain in the absence of exon 9A.
Splicing is a widespread process to generate functionally dierent proteins from a single gene. For example, expression of the mammalian HSF4 gene generates an activator and a repressor of heat shock genes by alternative splicing (Tanabe et al., 1999) . Both isoforms of HSF4 (named HSF4a and HSF4b, respectively) bind to DNA as homotrimers. However, HSF4a inhibits the constitutive expression of heat shock genes while HSF4b acts as a transcriptional activator. As another example, alternative splicing of the primary transcript of the Oct-2 gene which plays an important role in the nervous system yields a variety of dierent mRNAs encoding Oct-2 isoforms which either activate or inhibit gene expression (Latchman, 1996) . The mechanisms by which dierential splicing generates activators or repressors of transcription from the same gene are quite divergent. While both isoforms of HSF4, like both forms of B-Myb, bind to DNA but dier in their transactivation potential, the alternatively spliced isoforms ATF3 and ATF3 delta Zip realize activation and repression of transcription in a dierent manner. ATF3 is a member of the mammalian activating transcription factor/cAMP responsive element binding protein (ATF/CREB) family of transcription factors. ATF3 represses transcription by stabilization of inhibitory co-factors at the promotor. The alternatively spliced isoform ATF3 delta zip lacks the leucine zipper domain and does not bind to DNA, therefore ATF3 delta Zip stimulates transcription by sequestering inhibitory co-factors away from the promotor .
Not only alternative splicing but also use of dierent AUG codons for initiation of translation leads to transcription factors which dier in their transcription activation potential. For example, the mRNA of the CCAAT/enhancer binding protein (C/EBP) beta is translated into several dierent protein species due to dierential usage of alternative translation initiation codons. One of these proteins, referred to as LIP, lacks the transactivation domain of C/EBP b and acts as a transcriptional inhibitor (Descombes and Schibler, 1991) . Similar observations have been made for C/ EBP a (Ossipow et al., 1993) . It is clear from these and other examples that the generation of both activating as well as inhibitory isoforms of the same transcription factor is not a rare event.
The results reported here demonstrate that B-myb encodes both an activator and an inhibitor of transcription. As for the examples described above it is clear that also in the case of BMyb a primary mechanism of regulation of its transcriptional activity relays on the dierential assembly of activatory and inhibitory domains, with post-translational modi®cations and protein-protein Further experiments aimed at understanding the function of the two B-Myb isoforms in the context of regulated progression through the cell division cycle are in progress in our laboratory.
Materials and methods

Expression vectors
Expression vectors for full-length mouse B-Myb (pMuBMEx9A+) and for the splice variant lacking exon 9A (pMuBMEx9A7) have been described before (Kamano et al., 1995) . The expression vector pGal4MuBMEx9A+DDBDD3 which encodes a Gal4/B-Myb fusion protein lacking the BMyb DNA-binding domain and the inhibitory C-terminal domain of B-Myb has been described before (Ziebold et al., 1997 ). An expression vector for human cyclin A was obtained from R Weinberg (Hinds et al., 1992) . The expression vectors Gal4 B-Myb D1, Gal4 B-Myb D2, Gal4 B-Myb D3 and Gal4 B-Myb D5 encode fusion proteins of Gal4 DNA-binding domain and amino acids 168 ± 280, 240 ± 371, 345 ± 530 and 240 ± 530 of B-Myb respectively. They were generated by PCR ampli®cation of the corresponding fragments using pMuBMEx9A+ as a PCR template. For Gal4 B-Myb-D4 the vector pMuBMEx9A7 was used as template DNA (amino acids 240 ± 318 and 459 ± 530 of pMuBMEx9A+). 5' primers used for PCR contained an in-frame EcoRI site, and 3' primers introducing a stop codon contained an additional XbaI site. The PCR-products were cloned in the pCR 1 2.1-TOPO vector (Invitrogen), sequenced and subcloned as EcoRI/XbaI fragments between the EcoRI and XbaI sites of pCMVGal1 (Mink et al., 1997) .
Reporter genes, transfections, luciferase and b-galactosidase assays The Gal4-inducible reporter plasmid pG5E4-38Luc has been described (Kamano et al., 1995) . The Myb inducible reporter plasmid pGl3-3xATk was constructed by subcloning a BglII/ KpnI fragment from the reporter plasmid p3xATkLuc (Ness et al., 1989) between the BglII and KpnI sites of pGL3 (Promega). pCMVb was otained from Clontech. QT6 cells were transfected as described (Ziebold et al., 1997) . The amounts of expression vectors given in the ®gure legends were used for single 10 cm tissue culture dishes. Cells were harvested 24 h after transfection. Preparation of cell extracts, luciferase and b-galactosidase assays were performed as described (Burk et al., 1993) .
Western blotting
Immunostaining of B-Myb proteins transferred to nitrocellulose was performed as described (Kamano et al., 1995) . BMyb proteins were detected with a polyclonal rabbit antiserum raised against the B-Myb DNA-binding domain (Kamano et al., 1995) . Gal4/B-Myb fusion proteins were detected by using a monoclonal antibody against the Gal4 DNA-binding domain (RK5C1, St. Cruz Biotechnology).
Subcellular fractionation
QT6 cells were harvested 24 h after transfection and were washed two times with hypotonic buer (10 mM HEPES pH 7.8, 2 mM MgCl 2 , 5 mM KCl). Pelleted cells were resuspended in 200 ml hypotonic buer containing 0.5% NP-40 and incubated for 10 min on ice. The nuclei of the cells were then collected by centrifugation (5', 10 000 r.p.m., 48C). The pelleted nuclei were analysed by SDS ± PAGE. The supernatant containing cytosolic proteins was transferred to a new tube, precipitated with 5 volumes of acetone for 10 min at 7708C and analysed by SDS ± PAGE.
